Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$60.12 USD

60.12
138,732

+0.46 (0.77%)

Updated Oct 17, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies

by Zacks Equity Research

Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?

by Zacks Equity Research

Here is how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

by Zacks Equity Research

ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR amyloidosis with cardiomyopathy.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

by Zacks Equity Research

The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.

MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study

by Zacks Equity Research

MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.

JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study

by Zacks Equity Research

Data from a late-stage study showed that Jazz's Zepzelca, combined with Roche's Tecentriq, improved survival rates in certain patients with small-cell lung cancer.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises

by Zacks Equity Research

Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%

by Zacks Equity Research

LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug

by Zacks Equity Research

Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.

PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program

by Zacks Equity Research

PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study

by Zacks Equity Research

The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.

Wall Street Analysts Predict a 42.98% Upside in ANI (ANIP): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 43% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA

by Zacks Equity Research

Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.

NTLA Begins Phase III Study on Hereditary Angioedema Candidate

by Zacks Equity Research

Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

by Zacks Equity Research

AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag

by Zacks Equity Research

Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.

SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

by Zacks Equity Research

Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.

Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus

by Zacks Equity Research

As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why

by Zacks Equity Research

The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on the stock.

ONCY Stock Up on Regulatory Update From Breast Cancer Program

by Zacks Equity Research

Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.

Pacira's Exparel Receives Permanent New Product-Specific J-Code

by Zacks Equity Research

PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.